Journals / Ata-Kimya Dergisi / 2021 / Cilt: 1 - Sayı: 1

In silico study and structure-activity relations of glucose-bound coumarin derivatives against the NSP12 protein of SARS-CoV-2

SARS-CoV-2'nin NSP12 proteinine karşı glukoza bağlı kumarin türevlerinin in silico çalışması ve yapı-aktivite ilişkileri

Pages
29–37
Publication Date
2021-11-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study is also thought to give insight to scientists working for the design of SARS-CoV-2 antiviral drugs in terms of the structure activity relationship between coumarin and its functional groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, designs of antiviral drug candidates that may be effective against SARS-CoV-2 virus were performed.
📊
Key Findings & Data:Molecular docking was used to explore the effect of coumarin and its derivatives, which have antiviral action, on RNA polymerase NSP12, one of the key proteins of the coronavirus.
💡
Conclusion & Impact:This study is also thought to give insight to scientists working for the design of SARS-CoV-2 antiviral drugs in terms of the structure activity relationship between coumarin and its functional groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:SARS-CoV-2 · COVID-19 · Koronavirüs

Abstract

In this study, designs of antiviral drug candidates that may be effective against SARS-CoV-2 virus were performed. Molecular docking was used to explore the effect of coumarin and its derivatives, which have antiviral action, on RNA polymerase NSP12, one of the key proteins of the coronavirus. The sugar group on coumarins was selected to increase hydrophilicity, and the amide groups were diversified to investigate selectivity. Coumarins containing 3-(p-phenylamidomorpholine), 3-(p-phenylamidopiperazine), and 3-(p-phenylamidopiperidine) groups had the best docking scores, with binding affinities of -10.1 kcal/mol, -10.1 kcal/mol, and -10.0 kcal/mol, respectively. The pharmacokinetic and toxicokinetic properties of compounds were estimated close to reality using various databases, and their values were close to the target values needed for a compound to become a drug. This study is also thought to give insight to scientists working for the design of SARS-CoV-2 antiviral drugs in terms of the structure activity relationship between coumarin and its functional groups.

Özet

Bu çalışmada SARS-CoV-2 virüsüne karşı etkili olabilecek antiviral ilaç adaylarının tasarımları yapılmıştır. Moleküler yerleştirme, antiviral etkiye sahip kumarin ve türevlerinin, koronavirüsün temel proteinlerinden biri olan RNA polimeraz NSP12 üzerindeki etkisini araştırmak için kullanıldı. Kumarinlerdeki şeker grubu, hidrofilisiteyi arttırmak için seçilmiş ve seçiciliği araştırmak için amid grupları çeşitlendirilmiştir. 3-(p-fenilamidomorfolin), 3-(p-fenilamidopiperazin) ve 3-(p-fenilamidopiperidin) gruplarını içeren kumarinler, sırasıyla -10.1 kcal/mol, -10.1 kcal/mol, and -10.0 kcal/mol bağlanma afiniteleriyle en iyi yerleştirme puanlarına sahipti. Bileşiklerin farmakokinetik ve toksikokinetik özellikleri, çeşitli veri tabanları kullanılarak gerçeğe yakın olarak tahmin edildi ve değerleri, bir bileşiğin ilaca dönüşmesi için gereken hedef değerlere yakındı. Bu çalışmanın ayrıca SARS-CoV-2 antiviral ilaçların tasarımı için çalışan bilim insanlarına kumarin ve fonksiyonel grupları arasındaki yapı aktivite ilişkisi açısından fikir vereceği düşünülmektedir.

🔖

Cite This Article

ÇELİK, E., ÖZDEMİR, M., YALÇIN, B., KÖKSOY, B. (2021). In silico study and structure-activity relations of glucose-bound coumarin derivatives against the NSP12 protein of SARS-CoV-2. Ata-Kimya Dergisi, Cilt: 1 - Sayı: 1, 29–37. https://ajindex.com/articles/850420

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. REFERENCES [1] Heidary, F., Gharebaghi, R. “Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen” The Journal of antibiotics, (2020),73(9), 593-602. [2] Lai, C-C., Shih, T-P., Ko, W-C., Tang, H-J., Hsueh, P-R. “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges” International journal of antimicrobial agents, (2020), 55(3), 105924. [3] Xu, P., Zhou, Q., Xu, J. “Mechanism of thrombocytopenia in COVID-19 patients” Annals of hematology, (2020), 99(6), 1205-1208. [4] Jain U. Effect of COVID-19 on the Organs. Cureus. 2020;12(8). [5] Khailany, R.A., Safdar, M., Ozaslan, M. “Genomic characterization of a novel SARS-CoV-2” Gene reports, (2020), 19, 100682. [6] Mittal, A., Manjunath, K., Ranjan, R.K., Kaushik, S., Kumar, S., Verma, V. “COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2” PLoS pathogens, (2020), 16(8), e1008762. [7] Hall, Jr D.C., Ji, H-F. “A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease” Travel medicine and infectious disease, (2020), 35, 101646. [8] Dehelean, C.A., Lazureanu, V., Coricovac, D., Mioc, M,. Oancea, R., Marcovici, I., et al. “SARS-CoV-2: repurposed drugs and novel therapeutic approaches—insights into chemical structure—biological activity and toxicological screening” Journal of clinical medicine, (2020), 9(7), 2084. [9] Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., et al. “Structural and functional basis of SARS-CoV-2 entry by using human ACE2” Cell, (2020), 181(4), 894-904. [10] Hati, S., Bhattacharyya, S. “Impact of Thiol–Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor” ACS omega, (2020), 5(26), 16292-16298. [11] Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., et al. “The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice” Nature, (2020), 583(7818), 830-833. [12] Sun, X-Y., Liu, T., Sun, J., Wang, X-J. “Synthesis and application of coumarin fluorescence probes” RSC Advances, (2020), 10(18), 10826-10847. [13] Küpeli Akkol, E,. Genç, Y., Karpuz, B., Sobarzo-Sánchez, E., Capasso, R. “Coumarins and coumarin-related compounds in pharmacotherapy of cancer” Cancers, (2020), 12(7), 1959. [14] Pivetta, T., Valletta, E., Ferino, G., Isaia, F., Pani, A., Vascellari, S., et al. “Novel coumarins and related copper com